Skip to content

Establishing Global Reference Values for Human Milk

Establishing Global Reference Values for Human Milk Composition in a Multi-Center Collaborative Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03254329
Acronym
MILQ
Enrollment
2000
Registered
2017-08-18
Start date
2017-09-01
Completion date
2021-11-30
Last updated
2021-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Milk Nutrient Reference Values

Keywords

human milk, micronutrients, lactation, milk volume, milk composition, reference values

Brief summary

The primary purpose of the proposed research is to establish Reference Values (RVs) for micronutrients (MN) and macronutrients in human milk. The investigators' research to date has revealed highly variable milk MN concentrations among populations, and very low values in some low income countries (LICs) likely caused by poor maternal status and/or diet but RVs are needed to interpret these values. During the past year the investigators conducted a review of human milk nutrient composition, and formed a Technical Advisory Group (TAG) which developed the current proposal. Here, the investigators are conducting a longitudinal project on well-nourished women and infants. The Mothers, Infants and Lactation Quality (MILQ) study is a multi-center cohort project, investigating breast milk nutrient composition in well-nourished women across the first 8.5 months of lactation in four different populations. The countries involved are Denmark, Brazil, Bangladesh and The Gambia. Exclusive breastfeeding is an eligibility criterion up until the second post-partum study visit (between 1 - 3.4 months postpartum), with the exception of the first week after delivery. Other data collected on mothers and infants, including maternal and infant nutrient intake and status, morbidity, milk volume, and infant development, will inform interpretation and support application of the results. While the priority is to develop RVs for MN, other analyses will include human milk oligosaccharides (HMOs) and proteins, and free amino acids (FAA) in infant plasma. Thus, with the samples obtained the investigators will perform (a) laboratory analyses of milk, plasma and urine nutrients to construct RVs for global application, (b) analyses of HMOs and proteins in milk, and (c) metabolomic analysis of FAA and other metabolites in infant plasma. By request of the Bill and Melinda Gates Foundation (BMGF), colostrum and fecal microbiota samples will also be collected and stored for later analyses.

Detailed description

The investigators will collect breast milk samples at four visits, at 2-3 days after birth (colostrum) and at 1-3.4, 3.5-5.9, and 6-8.5 months of lactation from well-nourished mothers age ≥18 to ≤40 years, in a systematic, identical way in four countries. The four sites are: Copenhagen, Denmark; Banjul, The Gambia; Rio de Janeiro, Brazil; and Mirpur, Dhaka, Bangladesh. The most important site selection criteria were that multiple micronutrient supplements are not consumed after week 28 of pregnancy; maternal diet is adequate but consumption of highly fortified foods is limited; and exclusive breastfeeding is 60% at 4 months. In order to have 250 women and infants per site complete the study at 8.5 months, approximately 500 women will be recruited during the third trimester of pregnancy. This should allow for mothers and infants not meeting study eligibility criteria in pregnancy or early lactation, and drop-outs from the study. Recruitment during pregnancy will increase the opportunity to locate and recruit women since recruitment in the immediate post-delivery period will be difficult. It will also enable the women to be counselled on the importance of exclusive breastfeeding (EBF). Colostrum will be collected at 2-3 days postpartum for future analysis. The first collection of mature milk will occur between 1 and 3.4 months postpartum, when maternal and infant blood samples will also be collected on all participants. At the final two visits, in addition to milk collection, blood will be taken from all mothers but only half of the infants each time, primarily for the assessment of micronutrient status. A requirement is that infants must be EBF in the 1-3.4 month period, and breastfed (BF) in the second and third period. Longitudinal measurements on the same mother after the BF period are not necessary for statistical reasons, as the investigators are not creating RVs for change in milk composition. The investigators expect that due to attrition and cessation of BF, the sample size will need to be augmented in later months; the alternative would have been to recruit and measure many more women in earlier stages in order to have an adequate sample size in the 7-8.5 month interval, which would be a much less efficient approach. Therefore after 6 months, if women are not breastfeeding, additional lactating women will be recruited from the group that was not EBF in the 3.4 month period, or from the local health center or community. At all three points of mature milk collection the investigators will measure breast milk volume; diet, anthropometry and morbidity of the mother and infant; and infant development at 3.5-5.9 and 6 to 8.5 months; and will collect infant fecal samples for future analyses of the microbiome. Milk volume will be measured at three sites using the International Atomic Energy Agency's protocol that requires dosing the mother with deuterated water and collecting maternal and infant saliva urine samples at 0, 1, 2, 3, 4, 13 and 14 days after the dose. In Denmark breast milk volume will be measured by 24 hour infant weighing. Most of the laboratory analyses will be conducted at the United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center (WHNRC) in Davis, California. Other analyses will be performed in the Department of Chemistry at University of California, Davis (HMOs and other bioactive compounds in milk), and the Swiss Federal Institute of Technology in Zurich (iodine status). RVs will be constructed following the methods and principles developed for the World Health Organization (WHO) Child Growth Standards and the Intergrowth-21st Project. An add-on study Evaluation of maternal insulin resistance, metabolic and inflammatory biomarkers for prediction of successful initiation and duration of breastfeeding is being conducted at the Danish site and was approved by The Regional Committee on Health Research Ethics with (H-17015174). The aims of the add-on study are to evaluate if maternal metabolic and inflammatory biomarkers can predict successful initiation and duration of breastfeeding in a population of healthy non-obese Danish women, to evaluate the impact of maternal inflammatory biomarkers during pregnancy on the offspring's growth and risk factors for later disease, and to relate the impact of maternal metabolic and inflammatory biomarkers during pregnancy on breastfeeding behavior and on the offspring's growth and risk factors for later disease in this population to corresponding outcomes in an established cohort of infants born of obese mothers.

Interventions

OTHERAssessment of human milk nutrient composition

Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.

Sponsors

University of Copenhagen
CollaboratorOTHER
Medical Research Council Unit, The Gambia
CollaboratorOTHER
International Centre for Diarrhoeal Disease Research, Bangladesh
CollaboratorOTHER
Universidade Federal do Rio de Janeiro
CollaboratorOTHER
Bill and Melinda Gates Foundation
CollaboratorOTHER
USDA, Western Human Nutrition Research Center
Lead SponsorFED

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

for Mother * No vitamin-mineral supplements during third trimester of pregnancy or during lactation except for iron + folic acid, also vitamin D and Ca in Denmark. * Low habitual intake of highly-fortified foods (iodized salt excepted). * No relevant past or current medical problems including gestational diabetes or pre-eclampsia. * Singleton delivery, not preterm. * BMI ≥18.5 to \<30.0 kg/m2, height ≥150 cm. * Mid-upper arm circumference (MUAC) ≥23 and ≤33 cm in pregnancy * Consuming a nutritionally adequate diet i.e. not vegan or macrobiotic, ≥5 food groups/d each ≥15g. At screening this information will be collected with a locally-appropriate and validated food frequency questionnaire. * Non-anemic in pregnancy (Hb \>100 g/L) * Alcohol intake ≤5 units (50 mL pure alcohol)/week. * Non-smoker. Inclusion Criteria for Infant * Birth weight 2500-4200 g, 37-42 weeks of gestation. * No congenital malformations that interfere with feeding or growth and development.

Exclusion criteria

at 1 to 3.4 Months Postpartum * Cessation of or non-exclusive breastfeeding. * Serious maternal illness. * Infant length-for-age, weight-for-age or weight-for-length \< -2 Z.

Design outcomes

Primary

MeasureTime frameDescription
Change in vitamin and mineral concentrations in human breast milkBreast milk samples collected 1-3.4, 3.5-5.9, and 6-8.5 months postpartumTo establish reference values, the vitamin and mineral concentrations will be measured in milk of well-nourished women

Secondary

MeasureTime frameDescription
Infant length1-3.4, 3.5-5.9, and 6-8.5 monthsmeasured in cm
Variation in other constituents of human breast milkBreast milk samples collected at 1-3.4, 3.5-5.9, and 6-8.5 months postpartumMacronutrients, and human milk oligosaccharides and proteins will be analyzed
Micronutrient status of mothers and infantsBlood and urine samples surveyed at 1-3.4, 3.5-5.9, and 6-8.5 months postpartumVitamin and mineral status of mothers and infants will be assessed in blood and urine
Maternal body mass index1-3.4, 3.5-5.9, and 6-8.5 months postpartumMaternal weight and height will be combined to determine body mass index (kg/m2)
Milk volume1-3.4, 3.5-5.9, and 6-8.5 months postpartumMeasurements of usual daily milk volume using deuterated water or, in Denmark, 24 hour infant weighing
Maternal and infant iodine status1-3.4, 3.5-5.9, and 6-8.5 months postpartumUrinary iodine; thyroid stimulating hormone, thyroglobulin and thyroxine in dried blood spots
Milk iodine1-3.4, 3.5-5.9, and 6-8.5 months postpartumMilk iodine
Maternal nutrient intake during pregnancyMeasured during gestational week 35-37Assessment of dietary intake by two days 24-hour recall in Denmark and Brazil
Maternal nutrient intake1-3.4, 3.5-5.9, and 6-8.5 months postpartumAssessment of dietary intake by two days 24-hour recall
Infant nutrient intake1-3.4, 3.5-5.9, and 6-8.5 monthsAssessment of dietary intake by two days 24-hour recall of the infant's diet
Infant dietary habits1-3.4, 3.5-5.9, and 6-8.5 monthsAssessment of dietary intake by diet habits questionnaire
Maternal weight1-3.4, 3.5-5.9, and 6-8.5 months postpartumMeasure of weight in kilograms (kg)
Infant weight1-3.4, 3.5-5.9, and 6-8.5 monthsMeasure of weight in grams (g) or kilograms (kg)
Infant growth1-3.4, 3.5-5.9, and 6-8.5 months postpartumInfant weight and length will be aggregated to determine infant growth status
Maternal body composition1-3.4, 3.5-5.9, and 6-8.5 months postpartumAssessment of body composition by bioimpedance in Denmark, The Gambia, and Brazil only.
Infant body composition1-3.4, 3.5-5.9, and 6-8.5 monthsAssessment of body composition by Air Displacement Plethysmography, in The Gambia, and by bioimpedance in Denmark and Brazil.
Infant morbidity1-3.4, 3.5-5.9, and 6-8.5 monthsData collected from mothers on infant health
Infant development6-8.5 monthsAges and Stages questionnaire
Infant motor development3.5-5.9 and 6-8.5 monthsInfant motor development measured using a World Health Organization (WHO) assessment of motor milestones
Change in infant microbiome1-3.4, 3.5-5.9, and 6-8.5 monthsDNA analyses of infant gut bacteria derived from fecal samples
Change in maternal microbiomeCollected at gestational week 28-40, and 1-3.4, 3.5-5.9, and 6-8.5 months postpartumDNA analyses of maternal gut bacteria derived from fecal samples in The Gambia and Brazil only
Maternal Glucose ToleranceMeasured once at gestational week 28-30In Denmark only, an Oral Glucose Tolerance Test will be performed. Fasting blood sugar (BS), and BS at 1 and 2 hours after glucose beverage.
Maternal Hemoglobin A1c (HbA1c)Measured once at gestational week 28-30In Denmark only, maternal Hemoglobin A1c will be measured in whole blood
Maternal markers of insulin sensitivityMeasured once at gestational week 28-30In Denmark only, a serum sample will be collected and stored for measurement of insulin (mU/l), c-peptide (pmol/l), and leptin (ng/l)
Maternal lipid panelMeasured once at gestational week 28-30In Denmark only, a serum sample will be collected and stored for measurement of a lipid profile including Total Cholesterol, High Density Lipoprotein-cholesterol, Low Density Lipoprotein-cholesterol, Very Low Density Lipoprotein-cholesterol, and Triglycerides in mmol/l).
Maternal inflammatory markersMeasured once at gestational week 28-30In Denmark only, a serum sample will be collected and stored for measurement of high sensitivity C-reactive protein (mg/l).
Maternal height1-3.4, 3.5-5.9, and 6-8.5 months postpartummeasured in centimeters (cm)

Countries

Bangladesh, Brazil, Denmark, The Gambia

Contacts

Primary ContactLindsay H Allen, PhD
lindsay.allen@ars.usda.gov530 752 5268
Backup ContactSetareh Shahab-Ferdows, PhD
setti.shahab-ferdows@ARS.USDA.GOV530 752 9540

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 19, 2026